NewTimeSpace News: On February 27, Hong Kong's innovative drug sector rebounded at the market open. JOINN Laboratories surged over 5%, WuXi Biologics jumped more than 4%, while Pharmaron, Innovent Biologics, and Junshi Biosciences all trended higher. CSOP Hang Seng Biotech ETF(03174.HK) opened up over 2%.

CSOP Hang Seng Biotech ETF(03174.HK), issued by CSOP Asset Management and listed on the Hong Kong Stock Exchange, tracks the Hang Seng Biotechnology Index. This is an index fund focused on Hong Kong-listed biotechnology leaders, characterized by high volatility and elasticity, suitable for investors bullish on innovative drugs, CXO, vaccines, gene therapy and other segments.

On the industry news front, Zai Lab announced its Q4 and full-year 2025 financial results on February 26, 2026. The company reported total annual revenue of $460.2 million (approximately RMB 3.235 billion), representing a 15% year-over-year increase. Q4 revenue reached $127.6 million (approximately RMB 897 million), up 17% year-over-year. Full-year net loss narrowed to $175.5 million, with cash reserves of $789.6 million.

Data shows that China's innovative drug License-out transactions reached a record $135.7 billion in 2025. Since the beginning of 2026, blockbuster partnerships have continued to emerge. Beyond Innovent, two mega-BD deals in January—CSPC-AstraZeneca ($18.5 billion) and RemeGen-AbbVie ($5.6 billion)—fully validated the global value of domestic innovative drug pipelines.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.